Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge.
Curr Opin Cardiol
; 35(2): 178-186, 2020 03.
Article
in En
| MEDLINE
| ID: mdl-31804229
ABSTRACT
PURPOSE OF REVIEW The aim of this article is to provide practical recommendations on safe initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors to in-patients as well as management of those who are already on SGLT2 inhibitors. RECENT FINDINGS:
Robust data from stable outpatient cohorts indicate that the SGLT2 inhibitors are associated with clinically meaningful reductions in major adverse cardiovascular events, lower rates of hospitalization for heart failure, and a reduction in major kidney outcomes There is however a lack of information on how to initiate and manage SGLT2 inhibitors in an acute in-patient setting.SUMMARY:
SGLT2 inhibitors may be cautiously appropriate for in-patients if all the criteria for safe use are met but good clinical judgment must prevail. Temporary withholding of SGLT2 inhibitors is appropriate in hospitalized patients during a period of stress and/or insulinopenia.
Full text:
1
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
Type of study:
Guideline
Limits:
Humans
Language:
En
Year:
2020
Type:
Article